The development of differentiation agents for the treatment of prostate cancer.
Publication/Presentation Date
10-1-2003
Abstract
Given their novel mechanisms of action and relatively favorable toxicity profiles, differentiation agents have been the focus of much investigation in the field of oncology. Among the most well studied of these agents in prostate cancer have been the retinoids, vitamin D, peroxisome-proliferator-activated receptor gamma (PPARgamma) ligands, and, most recently, the histone deacetylase (HDAC) inhibitors. While the clinical activity of these agents has been limited, several obstacles to the development of these novel drugs have become apparent. A lack of validated measures of outcome and uncertainty regarding the appropriate disease states in which to test these agents have led to difficulty in trial design. Furthermore, a better understanding of the biologic targets and genes manipulated by these therapies is required such that more potent and selective drugs may be developed. By overcoming these obstacles, the full potential of this therapeutic class may be realized.
Volume
30
Issue
5
First Page
689
Last Page
697
ISSN
0093-7754
Published In/Presented At
Galsky, M., & Kelly, W. K. (2003). The development of differentiation agents for the treatment of prostate cancer. Seminars in oncology, 30(5), 689–697. https://doi.org/10.1016/s0093-7754(03)00355-5
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
14571416
Department(s)
Administration and Leadership
Document Type
Article